编者按：一年一度的临床肿瘤学界奥林匹克盛会——美国临床肿瘤学会（ASCO）年会将于当地时间6月2～6日在芝加哥举行。日前，ASCO会议官网公布了此次年会的日程和摘要题目。食管胃及肝胆胰肿瘤领域多项重磅研究即将公布，中国学者有4项研究入选口头摘要专场（Oral Abstract Session）和壁报交流专场（Poster Discussion Session），本文带您提前速览摘要题目。

 

食管胃癌

 

口头摘要专场（Oral Abstract Session）

 

Abstract: 4000

 

ATTRACTION-5: A phase 3 study of nivolumab plus chemotherapy as postoperative adjuvant treatment for pathological stage III (pStage III) gastric or gastroesophageal junction (G/GEJ) cancer.
ATTRACTION-5：一项将纳武利尤单抗联合化疗作为病理Ⅲ期胃或胃食管交界处（G/GEJ）癌术后辅助治疗的Ⅲ期研究
Presenter: Masanori Terashima, MD, PhD, FACS | Shizuoka Cancer Center, Devision of Gastric Surgery

 

Abstract: 4001

 

Perioperative PD-1 antibody toripalimab plus SOX or XELOX chemotherapy versus SOX or XELOX alone for locally advanced gastric or gastro-oesophageal junction cancer: Results from a prospective, randomized, open-label, phase II trial.
围手术期PD-1抗体特瑞普利单抗加SOX或XELOX化疗 vs. 单独SOX或XELOX化疗治疗局部进展期胃或胃食管交界处癌：一项前瞻性、随机、开放标签、Ⅱ期试验的结果
Presenter: 袁庶强教授 | 中山大学肿瘤防治中心 

 

Abstract: 4014 | Poster Bd #: 334

 

KEYNOTE-859 study of pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Outcomes in the protocol-specified PD-L1–selected populations.

帕博利珠单抗联合化疗治疗晚期HER2阴性胃或胃食管交界处（G/GEJ）癌的KEYNOTE-859研究：在指定方案的PD-L1选择人群中的结果

Presenter: Sun Young Rha, MD | Yonsei Cancer Center, Yonsei University Health System

 

Abstract: 4027 | Poster Bd #: 335

 

A phase 2 study (DisTinGuish) of DKN-01 in combination with tislelizumab + chemotherapy as first-line (1L) therapy in patients with advanced gastric or GEJ adenocarcinoma (GEA).
DKN-01联合替雷利珠单抗+化疗作为进展期胃或GEJ腺癌（GEA）患者的一线（1L）治疗：Ⅱ期DisTinGuish研究
Presenter: Samuel J Klempner, MD | Mass General Cancer Center

 

教育专场（Education Session）

 

摘要速递更新：Abstract#405736

 

Zolbetuximab联合 Capox治疗一线Claudin18.2阳性（CLDN18.2阳性）/HER-2阴性局部晚期（LA）或转移性胃/胃食管交界处（mG/GEJ）腺癌：Ⅲ期Glow研究主要结果
Updates on Abstract 405736: Zolbetuximab + Capox in 1L Claudin-18.2+ (CLDN18.2+)/HER2− Locally Advanced (LA) or Metastatic Gastric or Gastroesophageal Junction (mG/GEJ) Adenocarcinoma: Primary Phase 3 Results from Glow
Presenter: 徐瑞华教授  中山大学肿瘤防治中心 

 

肝胆胰肿瘤

 

口头摘要专场（Oral Abstract Session）

 

Abstract: 4002

 

Efficacy, safety and patient reported outcomes (PROs) from the phase III IMbrave050 trial of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation.

切除或消融治疗后有高复发疾病风险的肝细胞癌患者辅助阿替利珠单抗（atezo）+贝伐珠单抗（bev）vs. 主动监测的Ⅲ期IMbrave050试验：疗效、安全性和患者报告的结局（PROs）

Presenter: Masatoshi Kudo, MD, PhD | Kindai University Hospital

 

Abstract: 4003

 

Health-related quality of life (HRQoL) in the phase 3 KEYNOTE-966 study of pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) versus placebo plus gem/cis for advanced biliary tract cancer (BTC).

来自帕博利珠单抗联合吉西他滨和顺铂（gem/cis）vs. 安慰剂联合gem/cis治疗晚期胆道恶性肿瘤的Ⅲ期KEYNOTE-966的健康相关生活质量（HRQoL）结果

Presenter: Changhoon Yoo, MD, PhD | Asan Medical Center, University of Ulsan College of Medicine

 

Abstract: 4004

 

Outcomes by occurrence of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC).

不可切除肝细胞癌（uHCC）的Ⅲ期HIMALAYA研究中，应用tremelimumab（T）加度伐利尤单抗（D）的免疫介导不良事件（imAEs）的发生情况

Presenter: George Lau, MD | Humanity and Health Clinical Trial Center, Humanity and Health Medical Group

 

Abstract: LBA4005

 

Short-course neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer: A multicenter randomized phase-II trial (NORPACT-1).

短程新辅助FOLFIRINOX vs. 前期手术治疗可切除胰头癌：多中心随机Ⅱ期NORPACT-1试验

Presenter: Knut Jørgen Labori, MD PhD | Department of Hepato-Pancreato-Biliary Surgery, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo

 

Abstract: 4006

 

Liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): 12- and 18-month survival rates from the phase 3 NAPOLI 3 trial.

脂质体伊立替康+5-氟尿嘧啶/亚叶酸+奥沙利铂（NALIRIFOX） vs. 白蛋白紫杉醇+吉西他滨对于初治转移性胰腺导管腺癌（mPDAC）患者的疗效：Ⅲ期NAPOLI 3试验的12个月和18个月生存率

Presenter: Eileen Mary O'Reilly, MD | Memorial Sloan Kettering Cancer Center

 

Abstract: 4007

 

Tucatinib and trastuzumab for previously treated HER2-positive metastatic biliary tract cancer (SGNTUC-019): A phase 2 basket study.

图卡替尼和曲妥珠单抗用于既往治疗的HER2阳性转移性胆道癌：一项Ⅱ期篮子研究——SGNTUC-019研究

Presenter: Yoshiaki Nakamura, MD, PhD | National Cancer Center Hospital Japan East

 

Abstract: 4008

 

Results from the pivotal phase (Ph) 2b HERIZON-BTC-01 study: Zanidatamab in previously-treated HER2?amplified biliary tract cancer (BTC).

来自关键2b期HERIZON-BTC-01研究的结果：Zanidatamab对于既往治疗失败的HER2扩增胆道癌（BTC）的效果

Presenter: Shubham Pant, MD | MD Anderson Cancer Center

 

壁报交流专场（Poster Discussion Session）

 

Abstract: 4015 | Poster Bd #: 336

 

A phase 2 randomized, open-label, multicentre study of sintilimab and anlotinib in combination with gemcitabine plus cisplatin (GemCis) as first-line therapy in patients (pts) with advanced biliary tract cancer (BTC): SAGC.
信迪利单抗和安罗替尼联合吉西他滨加顺铂（GemCis）作为晚期胆道癌（BTC）患者的一线治疗：Ⅱ期随机、开放标签、多中心SAGC研究
Presenter: 应杰儿教授 | 中国科学院大学附属肿瘤医院（浙江省肿瘤医院） 

 

Abstract: 4016 | Poster Bd #: 337

 

A randomized study of consolidation chemoradiation (CTRT) vs observation after first-line chemotherapy (CT) in advanced gall bladder cancers (GBC): RACE-GB Study.
晚期胆囊癌一线化疗后巩固放化疗（CTRT）vs. 观察的随机研究：RACE-GB研究
Presenter: Sushma Agrawal, MD | SGPGI

 

Abstract: 4017 | Poster Bd #: 338

 

A multicenter, open-label, randomized phase II study evaluating adjuvant gemcitabine plus cisplatin (GC) and capecitabine with concurrent capecitabine radiotherapy (CAPE-RT) in patients with operated gallbladder adenocarcinoma (GBC): The GECCOR-GB trial.

评估辅助吉西他滨联合顺铂（GC）和卡培他滨联合卡培他滨同步放疗（CAPE-RT）在胆囊腺癌（GBC）患者中的疗效：多中心、开放标签、随机Ⅱ期GECCOR-GB试验

Presenter: Anant Ramaswamy, DM | Tata Memorial Hospital (HBNI)

 

Abstract: 4018 | Poster Bd #: 339

 

Clinical and genomic characterization of early-onset pancreatic cancer.

早发性胰腺癌的临床和基因组特征

Presenter: Florian Castet, MD | Gastrointestinal and Endocrine Tumor Unit, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus

 

Abstract: 4019 | Poster Bd #: 340

 

Investigating alterations in cancer driver genes and other potentially targetable mutations in patients with intrahepatic cholangiocarcinoma (iCCA) treated on the randomised phase III multicentre BILCAP clinical trial.

在随机Ⅲ期多中心BILCAP临床试验中，研究肝内胆管癌（iCCA）患者中癌症驱动基因和其他潜在靶向突变的改变

Presenter: Valerie Elizabeth Crolley, MBBS, MRCP | UCL-University College London (United Kingdom )

 

Abstract: 4020 | Poster Bd #: 341

 

Not all treated KRAS-mutant pancreatic adenocarcinomas are equal: KRAS G12D and survival outcome.

并非所有治疗过的KRAS突变胰腺癌都是同等的：KRAS G12D和生存结果

Presenter: Bach Ardalan, MD | Sylvester Comprehensive Cancer Center

 

Abstract: 4021 | Poster Bd #: 342

 

FOOTPATH: A randomized, open-label phase-2 study of liposomal irinotecan + 5-FU and folinic acid (NAPOLI) versus sequential NAPOLI and mFOLFOX6 versus gemcitabine/nab-paclitaxel in treatment-naïve metastatic pancreatic cancer (mPDAC).

脂质体伊立替康+ 5-FU和亚叶酸（NAPOLI） vs. 序贯NAPOLI和mFOLFOX6 vs. 吉西他滨/白蛋白紫杉醇治疗初治转移性胰腺癌（mPDAC）：随机、开放标签的Ⅱ期FOOTPATH研究

Presenter: Benedikt Westphalen, MD | Department of Medicine III and Comprehensive Cancer Center (CCC Munich LMU), University Hospital, LMU Munich, Munich, Germany

 

Abstract: 4022 | Poster Bd #: 343

 

Prospective evaluation of the utility of concurrent 18F-FDG PET/CT and 68Ga-DOTA-TOC imaging in gastroenteropancreatic neuroendocrine neoplasms (GEPNENs): The PETNET study.

18F-FDG PET/CT和68Ga-DOTA-TOC同步成像在胃肠胰腺神经内分泌肿瘤（GEPNENs）中应用的前瞻性评价：PETNET研究

Presenter: Joao Paulo Solar Vasconcelos, MD | BC Cancer, Vancouver Cancer Centre

 

Abstract: 4023 | Poster Bd #: 344

 

Neoadjuvant hepatic arterial infusion chemotherapy with FOLFOX could improve outcomes of resectable BCLC stage A/B hepatocellular carcinoma patients beyond Milan criteria: A multi-center, phase 3, randomized, controlled clinical trial.

采用FOLFOX新辅助肝动脉输注化疗可改善超米兰标准的可切除BCLC A/B期肝癌患者的预后：一项多中心、Ⅲ期、随机、对照临床试验

Presenter: 韦玮教授 | 中山大学肿瘤防治中心